Phosphorylation of ERα at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERα phosphorylation in breast cancer progression

N Sarwar1, J-S Kim1,2, J Jiang1,2, D Peston2, H D Sinnett3, P Madden4, J M Gee5, R I Nicholson5, A E Lykkesfeldt6, S Shousha2, R C Coombes1 and S Ali1

Departments of 1Oncology, 2Histopathology, 3Surgery and 4Social Science and Medicine, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK
5Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Cardiff, UK
6Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, DK-2100, Copenhagen Ø, Denmark

(Requests for offprints should be addressed to S Ali; Email: simak.ali@imperial.ac.uk)

Abstract

Oestrogen receptor-α (ERα) is an important prognostic marker in breast cancer and endocrine therapies are designed to inhibit or prevent ERα activity. In vitro studies have indicated that phosphorylation of ERα, in particular on serine 118 (S118), can result in activation in a ligand-independent manner, thereby potentially contributing to resistance to endocrine agents, such as tamoxifen and aromatase inhibitors. Here we report the immunohistochemistry (IHC) of S118 phosphorylation in 301 primary breast tumour biopsies. Surprisingly, this analysis shows that S118 phosphorylation is higher in more differentiated tumours, suggesting that phosphorylation at this site is associated with a good prognosis in patients not previously treated with endocrine agents. However, we also report that S118 phosphorylation was elevated in tumour biopsies taken from patients who had relapsed following tamoxifen treatment, when compared to pre-treatment biopsies. Taken together, these data are consistent with the view that S118 phosphorylation is a feature of normal ERα function and that increases in levels of phosphorylation at this site may play a key role in the emergence of endocrine resistance in breast cancer.

Endocrine-Related Cancer (2006) 13 851–861

Introduction

It is now clear that oestrogens play a central role in promoting breast cancer development and progression (Ali & Coombes 2002). In this respect, oestrogen action is mediated through the oestrogen receptors ERα and ERβ. Two-thirds of all primary breast cancers are known to express ERα, where its presence correlates with a better prognosis and likelihood of response to endocrine therapies. These findings have led to effective strategies aimed at preventing ER activation by reducing oestrogen levels using inhibitors of the oestrogen biosynthetic enzyme, aromatase (Johnston & Dowsett 2003) or, in the case of pre-menopausal women, using luteinizing hormone-releasing hormone (LHRH) agonists that act to inhibit oestrogen synthesis by suppression of ovarian function (Klijn et al. 2001).

In a second and highly effective approach in breast cancer treatment, tamoxifen is used as a selective oestrogen receptor modulator (SERM) that binds to ER, resulting in a conformational change, leading to inhibition of receptor activity. Thus, tamoxifen acts by competing with oestrogen for binding to ER, leading to inhibition of tumour growth. For many patients, tamoxifen is still the first line adjuvant agent in the treatment of ERα-positive breast cancer and provides
response in pre-menopausal women, as well as in post-
menopausal patients. Further, tamoxifen is an effective 
treatment for about half of all patients with ERα-
positive metastatic disease and prolongs disease-free 
for the incidence of contralateral invasive breast 
cancer, which has led to the proposal that it may be 
efficacious for breast cancer prevention. This hypo-
thesis has been confirmed by the results of several 
clinical trials with tamoxifen and another SERM, 
raloxifene, which show reduction in early incidence of 
breast cancer in women in high-risk groups (Powles 

A major complication in breast cancer treatment is 
the recognition that a substantial proportion of patients 
with ERα-positive breast cancer are de novo resistant 
to tamoxifen and many others who initially respond 
eventually acquire resistance (Ali & Coombes 2002, 
Ring & Dowsett 2004). Similar data have been 
obtained for other anti-oestrogens (Howell et al. 
2004) and for aromatase inhibitors, although third-
generation aromatase inhibitors may show delayed 
emergence of endocrine resistance, when compared 
with tamoxifen (Johnston & Dowsett 2003). The 
mechanisms underlying this resistance are still poorly 
understood and identification of the factors and 
pathways responsible for the development of resistance 
is therefore an important diagnostic and therapeutic 
challenge in breast cancer research.

It was originally proposed that resistance to 
endocrine agents involved the loss of ERα. However, 
it is now clear that the majority of tamoxifen-resistant 
tumours continue to express ERα (Robertson 1996, 
Ring & Dowsett 2004). Furthermore, tumours resistant 
to one form of endocrine therapy frequently respond to 
alternative endocrine treatment. For example, the 
aromatase inhibitor anastrozole has been shown to 
give response in around 30% of patients who had 
developed resistance to tamoxifen (Buzdar & Howell 
2001). Similar responses have been achieved following 
relapse on tamoxifen, with the potent anti-oestrogen 
ICI 182780, also known as Fulvestrant (Howell et al. 
1996). These findings provide in vivo evidence to 
indicate that ERα continues to play an important role in 
cancer cell growth in resistant tumours.

ERα is a member of the nuclear receptor super-
family of ligand-activated transcription factors, which 
is activated upon binding oestrogen (Chawla et al. 
2001). Oestrogen binding regulates ERα dimerization, 
intracellular localization and stability. Additionally, 
oestrogen binding stimulates ERα phosphorylation at 
several sites. The best studied of these is serine 118 
oestrogen-stimulated phosphorylation of S118 is 
mediated by the TFIIH kinase cdk7 and phosphoryl-
ation by cdk7 stimulates ERα activity (Joel et al. 1998, 
Furthermore, S118 phosphorylation can be induced 
by growth factors such as epidermal growth factor 
(EGF) and insulin-like growth factor (IGF), likely 
acting through direct phosphorylation of S118 by 
extracellular signal regulated kinase (ERK)1/2 mitogen-activated protein kinase (MAPK) (Kato 
et al. 1995). The growth factor and MAPK-induced 
phosphorylation of S118 can result in ligand-indepen-
dent activation of ERα (Bunone et al. 1996), which 
could be important in endocrine resistance, particularly 
given that MAPK activity is significantly increased in a 
large proportion of breast cancers (Sivaraman et al. 
1997) and elevated MAPK levels correlate with a poor 
response to endocrine therapies (Gee et al. 2001).

These findings suggest that ligand-independent 
activation of ERα through phosphorylation of S118 
may contribute to de novo and/or acquired resistance 
to endocrine therapies. In order to address this possibility 
we undertook a study to establish protocols for the 
immunohistochemical detection of ERα phosphory-
lated at S118 (P-S118) and to determine whether there 
is any relationship between levels of P-S118 and 
prognostic factors, survival and outcome of endocrine 
therapies.

Materials and methods

Human breast cancer samples

A total of 301 breast cancer cases were selected from the 
Charing Cross Hospital Breast Tumour Bank. All had 
been obtained from surgery carried out between 1981 
and 2003. The patient’s age at presentation, tumour 
grade, tumour size, ERα and progesterone receptor (PR) 
status were recorded, as were the dates of first relapse 
and of death. The majority of the tumours (94%) were 
ERα-positive at the time of initial surgery, as defined by 
ligand-binding assay or immunohistochemical staining. 
ERα and PR status were re-determined at the time of this 
study by immunohistochemical staining as described 
below. The clinico-pathological characteristics of the 
patient cohort are shown in Table 1. Response to 
endocrine therapy was determined by examining the 
clinical records of patients who had assessable disease 
and had received either neoadjuvant hormonal therapy 
or palliative hormonal treatments for metastatic disease. 
An additional 21 patients were identified and their
evaluation of response to treatment was determined using response evaluation criteria in solid tumours (RECIST) (Therasse et al. 2000). Time to progression was defined as the time from initial diagnosis to documented date of first relapse, and the time to death was defined as the time from initial diagnosis to death.

Clinical records of patients who had become resistant to hormonal therapy were also examined, and where a repeat biopsy had been obtained at relapse, whilst the patient was taking tamoxifen, or for patients who relapsed 1–5 years following the completion of tamoxifen treatment. Immunostaining for ERα and P-S118 was performed in breast cancer samples obtained before and after becoming resistant to hormonal therapy. The mean time to relapse in this group of patients was 51 months (n = 21; range 17–112 months following initial diagnosis). The study fulfilled the Institutional Ethics Review Board’s guidelines for the use of stored tissues samples.

**Immunohistochemistry**

Sections of 4 μm were cut from formalin-fixed, paraffin-embedded archival tissue blocks and mounted on 3-aminopropyltriethoxysilane (APES; Sigma) treated slides and dried overnight at 37 °C. Sections were placed in a 60 °C oven for 1 h prior to being dewaxed in xylene and rehydrated through graded alcohols. Endogenous peroxidase was blocked by immersing in 2% hydrogen peroxide in methanol for 10 min. Antigen retrieval was carried out by pressure cooking, using 10 mM citrate buffer pH 6.0 and immunohistochemistry (IHC) was performed as previously described (Taylor et al. 1998), using mouse monoclonal antibodies for P-S118 (cat. no. 2511; New England Biolabs, UK), activated mitogen-activated protein kinase (MAPK, cat. no. 4376; New England Biolabs, Herts, UK), ERα (cat. no. VP-E613; Vector Laboratories, Peterborough, UK), progesterone receptor (PR, cat. no. MU328-UC; Biogenex, USA) and a rabbit polyclonal antibody for c-erbB2 (cat. no. A0485; Dako). P-S118 levels were scored by a trained histopathologist, using the modified McCarty’s H-scoring system, which was based on the percentage of positive cells and the intensity of staining to provide a total score varying from 0 to 300. The staining was designated as negative (H-score < 50), weakly positive (+; H-score of 51–100), moderately positive (++; 101–200) or strongly positive (+++, 201–300) (McCarty et al. 1985). For determining the specificity of immunostaining for P-S118, the antibody was pre-incubated with a 100-fold molar excess of a peptide having the sequence 112-HPPPQLSPFLQPH-124 or the same peptide in which the serine residue was substituted by phosphoserine.

**Statistical analyses**

All statistical analyses were carried out using Stata 7 software (http://www.stata.com/). P-S118 scores were compared with different clinico-pathological features using the Pearson chi-squared test (χ tests) for categorical variables and the t and Mann–Whitney tests for continuous data. Association between S118 status and a number of clinico-pathological features is shown in Table 1.

### Table 1 Relationship between levels of ERα phosphorylated at serine 118 and clinical features

<table>
<thead>
<tr>
<th></th>
<th>P-S118- positive n (%)</th>
<th>P-S118-negative n (%)</th>
<th>Chi-squared</th>
<th>P value&lt;sup&gt;d&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;50</td>
<td>15 (70)</td>
<td>23 (30)</td>
<td>5.12</td>
<td>0.08</td>
</tr>
<tr>
<td>50–70</td>
<td>55 (82)</td>
<td>34 (18)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 70</td>
<td>13 (84)</td>
<td>6 (16)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Grade</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>32 (90)</td>
<td>4 (11)</td>
<td>22.35</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>II</td>
<td>149 (85)</td>
<td>27 (15)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>46 (60)</td>
<td>31 (40)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>11</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tumour size</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;2 cm</td>
<td>87 (79)</td>
<td>23 (21)</td>
<td>2.70</td>
<td>0.26</td>
</tr>
<tr>
<td>2–5 cm</td>
<td>113 (80)</td>
<td>29 (20)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 5 cm</td>
<td>17 (65)</td>
<td>9 (35)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>21</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nodal status</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>73 (79)</td>
<td>19 (21)</td>
<td>0.20</td>
<td>0.66</td>
</tr>
<tr>
<td>Positive</td>
<td>108 (73)</td>
<td>39 (27)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>57</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ERα</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>21 (42)</td>
<td>15 (79)</td>
<td>41.20</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Positive</td>
<td>83 (17)</td>
<td>48 (17)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PR</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>73 (71)</td>
<td>26 (27)</td>
<td>2.91</td>
<td>0.09</td>
</tr>
<tr>
<td>Positive</td>
<td>166 (82)</td>
<td>37 (18)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND&lt;sup&gt;e&lt;/sup&gt;</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>c-erbB2</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>66 (79)</td>
<td>17 (21)</td>
<td>1.02</td>
<td>0.31</td>
</tr>
<tr>
<td>Positive</td>
<td>16 (70)</td>
<td>7 (30)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND&lt;sup&gt;e&lt;/sup&gt;</td>
<td>156</td>
<td>39</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>P-MAPK</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>56 (89)</td>
<td>41 (44)</td>
<td>41.00</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Positive</td>
<td>180 (89)</td>
<td>22 (11)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND&lt;sup&gt;e&lt;/sup&gt;</td>
<td>0</td>
<td>5</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>P-S118-positive, H-score +, ++, +++.
<sup>b</sup>Percentage of cases in each horizontal group that were P-S118-negative.
<sup>c</sup>Pearson’s chi-squared test. The analysis was carried out using known samples only.
<sup>d</sup>A value of P < 0.05 denotes a statistically significant difference.
<sup>e</sup>ND denotes not determined.
features were investigated using chi-squared tests (where applicable Fisher’s exact tests were used). The Wilcoxon matched pairs signed rank test was used to determine whether there was a significant difference in the distribution of S118 phosphorylation before and after treatment failure. Survival was compared in each of the clinico–pathological features using log rank tests for equality of survivor function.

**Cell culture**

All cells were cultured at 37 °C in a humidified 5% v/v CO₂ incubator. MCF7 cells (ATCC, USA) were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% fetal calf serum (FCS). For preparation of whole cell lysates MCF7 cells plated on 9-cm dishes were transferred to DMEM lacking phenol red and containing 5% dextran-coated charcoal-stripped fetal calf serum (DSS) for 72 h, prior to the addition of oestradiol-17β (E₂; 10 nM), 4-hydroxytamoxifen (OHT; 100 nM), ICI 182780 (ICI; 100 nM), epidermal growth factor (EGF; 100 ng/ml) or phorbol myristate acetate (PMA; 100 ng/ml) for 15 min, as appropriate. The MAPK/ERK-kinase (MEK) inhibitor, U0126 (25 μM) was added 1 h prior to the addition of E₂, EGF or PMA. An equal volume of the solvent in which the different reagents were prepared was added to the appropriate samples to control for solvent effects. MCF7 Tam-R and matched MCF7 cells were maintained in RPMI 1640 lacking phenol red, supplemented with 5% DSS and containing OHT (100 nM), as described (Knowlden et al. 2003). MCF7/TAMR-4 have previously been described (Madsen et al. 1997). MCF7/TAMR-4 and matched MCF7 parental cells were maintained in DMEM/F12 lacking phenol red, supplemented with 1% FCS and containing 10⁻⁶ M tamoxifen, as described (Lykkesfeldt et al. 1994, Madsen et al. 1997), but may also be maintained with the addition of 100 nM of the more potent OHT, as used in this study. For preparing lysates from the Tam-R, MCF7/TAMR-4 and their respective matched parental MCF7 cells, the media were replaced by medium lacking FCS and in the absence of tamoxifen for 24 h prior to harvesting.

**Cell lysate preparation and immunoblotting**

Lysates were prepared essentially as previously described (Joel et al. 1998), by washing the cells with pre-warmed (37 °C) PBS. Then 0.5 ml of 2 × sample buffer (0.12 M Tris–HCl, pH 6.8, 4% SDS, 20% glycerol, 0.2 M dithiothreitol, 0.008% bromophenol blue), heated to 100 °C, was added to each 9-cm dish. The cells were scraped into 1.5 ml Eppendorf tubes in a heat block at 100 °C. The extracts were heated for 10 min, cooled on ice, aliquots obtained and then stored at −80 °C prior to use. Cell lysates were resolved using 10% SDS-PAGE and immunoblotting was carried out as previously described (Chen et al. 2002) using monoclonal antibodies for ERα (NCL-L-ER-6F11; Novocastra Laboratories, UK), P-S118 (cat. no. 2511; New England Biolabs, UK), ERK1, C-16 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), phosphorylated ERK1/2 MAPK (cat. no. 9106; New England Biolabs) and β-actin (C-2; Santa Cruz).

**Results**

**ERα phosphorylation in MCF7 breast cancer cells**

We have previously used antibodies specific to ERα phosphorylated at S118 and transient transfection of COS-1 cells to demonstrate that ERα is phosphorylated by ERK1/2 MAPK in a ligand-independent manner, but that the E₂-stimulated phosphorylation of S118 is not mediated by MAPK. Rather, the E₂-stimulated phosphorylation of S118 was shown to be mediated by the TFIIH protein kinase, Cdk7 (Chen et al. 2000, 2002). In order to confirm that two distinct signalling pathways in breast cancer cells also mediate S118 phosphorylation, total lysates were prepared from MCF7 cells treated with E₂, PMA or EGF. In the case of E₂, P-S118 levels were raised within 5 min, peaked at 30 min and started to fall after 45 min (data not shown). With PMA or EGF, P-S118 levels rose within 5 min, peaked at 15 min and started to fall thereafter (data not shown). Figure 1A shows the levels of P-S118 at 15 min following the addition of E₂, EGF or PMA. As expected, pretreatment with the MEK inhibitor, U0126, prevented S118 phosphorylation upon addition of EGF or PMA (Fig. 1B), but did not have any inhibitory effect on the stimulation of S118 phosphorylation by E₂ (Fig. 1C). Interestingly, the anti-oestrogens OHT and ICI 182780 also stimulated S118 phosphorylation (Fig. 1C). U0126 also failed to inhibit S118 phosphorylation stimulated by OHT and ICI.

The steady-state levels of P-S118 were next investigated in several MCF7 sub-lines derived by long-term culturing in the presence of tamoxifen in the culture medium (Lykkesfeldt et al. 1994, Knowlden et al. 2003). In the tamoxifen-resistant MCF7 sub-lines investigated the steady-state levels of P-S118 were elevated in the absence of E₂, OHT or serum, when compared with the parental MCF7 cells, as were levels of activated (phosphorylated) MAPK (Fig. 2). These data suggest that increased MAPK activity, as well as ERα phosphorylation and consequently increased ERα activity may feature in tamoxifen resistance in breast cancer.
Immunohistochemical detection of ERα phosphorylated at serine 118 in human breast tumours

The utility of the P-S118 antibody for IHC was explored by developing protocols using formalin-fixed, paraffin-embedded MCF7 tumours generated in nude mice (data not shown) and subsequently optimized using primary breast tumour blocks from several ERα-positive and ERα-negative tumours. In establishing the IHC methodology, there was no detectable immunostaining of ERα-negative cases with the P-S118 antibody (data not shown), whereas nuclear staining was detectable in many of the ERα-positive cases (Fig. 3A, B). The specificity of staining was determined by pre-in incubating the P-S118 antibody with a 100-fold excess of peptides encoding amino acids 112–124 of human ERα, in which a serine or a phosphoserine was present at position 118. Pre-incubation of the P-S118 antibody with the phosphorylated peptide resulted in loss of immunostaining (Fig. 3C), whereas the unphosphorylated peptide did not affect immunostaining (Fig. 3D). Further, competition was also performed using a peptide corresponding to amino acids 97–112 of human ERα and containing a phosphoserine at position 106 that is followed by a proline (as is S118), a previously described ERα phosphorylation site (Le Goff et al. 1994). Pre-incubation of the P-S118 antibody with this peptide, did not inhibit P-S118 staining (data not shown). Collectively, these data indicate that the P-S118 antibody specifically recognizes ERα phosphorylated at S118.

Tissue blocks from our cohort of 301 patients were sectioned for IHC to detect P-S118. In total, 282 (94%) of the tumours were ERα-positive, as determined by IHC. Of the 282 ERα-positive patients, 234 (83%) had detectable nuclear staining for P-S118.

Relationship between P-S118 staining and known prognostic features of breast tumours

Analysis of P-S118 positive cases by comparing the number of positive specimens in any given year showed that there was no statistical relationship between P-S118 staining and archival age, indicating that it is possible to evaluate relationships between P-S118 staining and prognostic features in this patient group. However, statistical analyses showed that there was no relationship between P-S118 staining (two
levels negative and positive) and tumour size, nodal status, PR and c-erbB2 status (Table 1). By contrast, there was a positive correlation of P-S118 with ERα ($P < 0.001$). Furthermore, there was a clear inverse relationship between P-S118 staining and tumour grade ($P < 0.001$), with lower grade tumours associated with higher H-scores for P-S118 staining ($P < 0.001$). There was also some evidence of an association between P-S118 and age ($P = 0.08$). However, P-S118 was not associated with survival, i.e. there was no statistically significant difference in survival between those positive and negative for P-S118 (log rank test for equality of survivor function $\chi^2$, 1 degree of freedom $Z = 1.43$, $P = 0.23$). Similarly there was no evidence of a statistically significant difference in survival for ERα (log rank test for equality of survivor function $\chi^2$, 1 degree of freedom $Z = 2.07$, $P = 0.15$), and c-erbB2 (log rank test for equality of survivor function $\chi^2$, 1 degree of freedom $Z = 1.59$, $P = 0.21$) in this cohort of patients. With respect to the other factors, there was a statistically significant difference in survival with regard to nodal status (log rank test for equality of survivor function $\chi^2$, 1 degree of freedom $= 14.82$, $P < 0.001$), grade (log rank test for equality of survivor function $\chi^2$, 2 degrees of freedom $= 13.46$, $P = 0.001$), tumour size (log rank test for equality of survivor function $\chi^2$, 2 degrees of freedom $= 16.22$, $P < 0.001$), age (log rank test for equality of survivor function $\chi^2$, 2 degrees of freedom $= 7.45$, $P = 0.02$) and PR (log rank test for equality of survivor function $\chi^2$, 1 degree of freedom $= 5.41$, $P = 0.02$).

IHC was also carried out using antibodies specific for activated MAPK. In total, 202 (68%) of the 296 cases immunostained scored positive for nuclear, phosphorylated (activated) MAPK. There was a positive correlation between phospho-MAPK staining and P-S118 staining ($P < 0.001$), as might have been expected, given that ERK1/2 MAPK phosphorylates ERα at S118. There was no evidence of a correlation between P-MAPK and survival (log rank test for equality of survivor function $\chi^2$, 1 degree of freedom $= 0.46$, $P = 0.50$).

**P-S118 levels do not predict for response to endocrine treatments following relapse on tamoxifen**

As described above, immunostaining of 301 primary breast cancer biopsies showed a positive correlation of P-S118 staining with ERα, as well as a negative correlation with tumour grade, and evidence for an association with PR status ($P = 0.09$). These data suggest that phosphorylation of S118 is a marker of better outcome.
prognosis and likelihood of response to endocrine treatment. We identified a group of patients who presented with ERα-positive primary breast cancer, were given adjuvant tamoxifen following surgical resection of the primary tumour and who then relapsed, at which point they received second-line endocrine agents. The patients in this group were subsequently scored as responders and non-responders according to RECIST criteria (Therasse et al. 2000). IHC of the primary breast cancer biopsies from these patients for P-S118 revealed that levels of P-S118 immunostaining were variable in both groups and there was no correlation between P-S118 staining and response.

Comparison of S118 phosphorylation in breast cancer pre- and post-tamoxifen treatment

The above data indicate that P-S118 levels in primary breast tumours are not predictive of response to endocrine therapies. However, for patients who initially respond and then relapse, it is possible that P-S118 levels increase during acquisition of resistance. Indeed, in MCF7-derived models of tamoxifen resistance P-S118 levels are elevated, as are levels of activated MAPK (Fig. 2). IHC was performed on biopsies from 21 patients who relapsed, either whilst receiving tamoxifen or after they had completed 5 years on tamoxifen, and for whom biopsy material taken prior to the initiation of tamoxifen treatment, was also available. Comparison of H-scores showed that P-S118 levels were increased following tumour regrowth (Table 2). Overall, there was a statistically significant difference in the distribution of S118 phosphorylation before and after treatment (\(z = -2.357, P=0.02\)). There were 2 comparisons in which S118 phosphorylation was higher pre-treatment, 11 where phosphorylation was higher post-treatment and 8 comparisons in which P-S118 levels were the same. The difference in P-S118 levels in pre- and post-treatment samples was not due to differences in total ERα levels, with no significant difference in the distribution of ERα before and after treatment (\(z = -0.815, P=0.42\)), whilst PR levels were significantly lower in the post-tamoxifen series, compared to the pre-treatment samples (\(z = 2.350, P=0.02\)).

In 11 cases, the patients relapsed whilst receiving tamoxifen. Since tamoxifen stimulates S118 phosphorylation, it is possible that the elevated P-S118 levels are due to the continued presence of tamoxifen in the blood and tissues. It has been estimated that significant levels of tamoxifen may remain in the blood for up to 6 weeks following discontinuation of administration. In the case of six of these patients, there was no difference in levels of P-S118 in the pre- and post-tamoxifen biopsies. For the other three cases, levels of P-S118 were increased in the resistant specimens. These data indicate that P-S118 levels do increase in a proportion of patients who have previously received tamoxifen and that the increase observed is not due solely to the presence of tamoxifen in the blood and tissues.

Discussion

We have previously used immunoblotting of extracts prepared from breast tumours to demonstrate the presence of ERα phosphorylated at S118 (Chen et al. 2002). In that study, S118 immunoblotting was carried out using an antibody specific for ERα phosphorylated at S118. Here we have employed a P-S118 antibody to develop an immunohistochemical protocol. Immunostaining of 301 breast cancer biopsies showed that a large proportion (84%) of ERα-positive breast tumours contain ERα phosphorylated at S118. As expected, statistical analysis demonstrated a positive correlation between P-S118 staining and ERα status. There was also a correlation between levels of P-S118 and tumour grade, with P-S118 levels being higher in lower grade tumours than in high-grade tumours. These findings indicate that phosphorylation of ERα at S118 is associated with a better prognosis, perhaps indicative of functional ERα, as suggested by previous reports showing that S118 phosphorylation is induced by oestrogen binding to ERα (Ali et al. 1993, Joel et al. 1995, 1998, Chen et al. 2000). Despite the correlation with tumour grade, there was no significant association between S118 phosphorylation and disease-free survival or overall survival in our data. Whilst these data were being analysed, another study examining P-S118 in 113 ERα-positive breast tumours reported similar

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Levels of serine 118 phosphorylation in primary tumours and biopsies taken following relapse after tamoxifen adjuvant therapya</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-S118</td>
<td>ERα</td>
</tr>
<tr>
<td>Increased</td>
<td>11</td>
</tr>
<tr>
<td>Decreased</td>
<td>2</td>
</tr>
<tr>
<td>No change</td>
<td>8</td>
</tr>
<tr>
<td>Total</td>
<td>21</td>
</tr>
<tr>
<td>(z)</td>
<td>-2.357</td>
</tr>
<tr>
<td>(P)</td>
<td>0.02</td>
</tr>
</tbody>
</table>

aImmunostaining was scored as −, +, ++, ++++, using the H-scoring method. Changes in H-score for matched pre- and post-treatment biopsies are shown.

The Wilcoxon matched pairs signed rank test was used to determine statistically significant differences.

A value of \(P < 0.05\) denotes a statistically significant difference.
findings, namely a negative association of P-S118 with tumour grade (Murphy et al. 2004b). Additionally, the latter study reports that phosphorylation at S118 correlates with longer disease-free survival and a trend towards better overall survival, a finding recently confirmed in another small study (Gee et al. 2005). This correlation is not held up in our considerably larger examination of 282 ERα-positive primary breast cancers.

The above studies have not reported on ERα-negative breast tumours immunostained for P-S118. Unexpectedly, in our study a small number of ERα-negative tumours stained positive for P-S118. Previous studies have shown that breast cancer cell lines that are ERα-negative by immunostaining and biochemically, can express ERα mRNA (Castles et al. 1993, 1995, Daffada et al. 1994, Poola et al. 2000). Similarly, breast tumours negative for ERα by IHC have been shown to express ERα mRNA (Shaw et al. 1996, Jarzabek et al. 2005). It is possible that ERα mRNA detected in ERα-negative breast cancer cells are alternative mRNAs, such as alternative splice variants, which may generate truncated ERα proteins some of which are not detected by IHC, such as the truncated ERα polypeptide generated by skipping of ERα exon 5 sequences that can be detected in the ERα-negative BT20 cell line (Castles et al. 1993) and in breast tumours (Desai et al. 1997). Some of these variant ERα proteins may be phosphorylated at S118, but not detected by IHC for ERα. It should be noted, however, that three out of the four P-S118-positive tumours had low levels of nuclear ERα immunostaining, with H-scores of 10–20. Breast tumours are scored ERα-negative for H-scores less than 50 (McCarty et al. 1985, Goulding et al. 1995), the method also used for this study. Therefore, the P-S118 positivity in these cases may be due to high-level phosphorylation of the small amounts of ERα in these cells.

Although our study and the publication by Murphy et al. (2004b) indicate that S118 phosphorylation is a predictor of positive response to endocrine therapies, IHC for phosphorylated (activated) MAPK (P-MAPK) demonstrated a highly significant correlation between levels of P-S118 and P-MAPK, as has also been described for a study involving 45 breast tumours (Murphy et al. 2004a). Breast cancer cell lines that show regrowth following long-term oestrogen deprivation and show increased ER activity, demonstrate increased levels of activated ERK1/2 MAPK and some dependence on MAPK activity for proliferation in cell culture, as well as in xenografts (Jeng et al. 1998, Santen et al. 2002). P-S118 levels are also higher in these cells (Martin et al. 2003). Levels of activated MAPK are also higher in tamoxifen-resistant MCF7 cells, as shown here. Moreover, ERK1/2 MAPK is overexpressed in some breast tumours (Sivaraman et al. 1997) and elevated MAPK activity has been correlated with lymph-node positivity (Adeyinka et al. 2002), decreased disease-free survival (Mueller et al. 2000, Gee et al. 2001) and poor response to endocrine therapy (Gee et al. 2001). In light of our finding of S118 phosphorylation being a good prognostic marker, the strong association of P-S118 with P-MAPK is surprising, since MAPK phosphorylation of S118 has been shown to result in ligand-independent activation of ERα (Bunone et al. 1996), which would indicate that S118 phosphorylation should correlate with reduced likelihood of response to endocrine therapies and hence poor prognosis. By contrast, although levels of P-S118 and P-MAPK were elevated in post-tamoxifen treatment biopsies compared to the pre-treatment biopsies, the change in P-S118 levels between pre- and post-tamoxifen biopsies was not associated with changes in P-MAPK levels in the same samples (data not shown). This indicates that other signalling pathways are involved in the increase in S118 phosphorylation, perhaps involving S118 phosphorylation by Cdk7 (Chen et al. 2000, 2002, Ito et al. 2004).

Collectively, the IHC data presented here for 301 unselected primary breast cancer biopsies show that ERα is differentially phosphorylated at S118 in breast tumours. However, the data presented here do not support the contention arising from in vitro studies, which indicate that S118 phosphorylation may be predictive of failure to respond to endocrine therapies. This is confirmed by IHC performed on primary tumours from a group of patients who were initially treated with tamoxifen, relapsed and subsequently either did or did not respond to further endocrine therapy. Indeed, our findings suggest that phosphorylation of S118 is a marker of functional oestrogen signalling in breast cancer, which is amenable to inhibition by use of endocrine therapies.

We also carried out IHC for ERα, PR, P-MAPK and P-S118 in biopsies from patients who subsequently received tamoxifen and for whom biopsies at relapse were identified. Changes in ERα and PR have previously been reported to be reduced at relapse or relapse in patients receiving tamoxifen (Johnston et al. 1995). In the current study, PR levels were significantly lower in the post-tamoxifen treatment compared to the pre-treatment specimens, in agreement with the above report, although we did not observe a significant reduction in ERα expression in our series, as judged by changes in H-score. Furthermore, it has been shown that levels of phosphorylated ERK1/2
S118 is dependent on its recruitment to ER shown). However, cdk7-mediated phosphorylation of pre- and post-tamoxifen treatment biopsies (data not shown) by cdk7, although levels of cdk7 were not different in other signalling pathways are required for the increase in P-S118 levels, perhaps due to S118 phosphorylation in tamoxifen resistance. In agreement with this idea the pre- and post-tamoxifen treatment specimens analysed here also demonstrated a significant increase in phosphorylated ERK1/2 levels.

Given these findings, the elevation in S118 phosphorylation in tamoxifen-resistant specimens was expected, especially as P-S118 levels in primary breast tumours were associated with levels of P-MAPK. However, there was no correlation between the increase in P-S118 levels and the increases in P-MAPK in the emergence of tamoxifen resistance, indicating that other signalling pathways are required for the increase in P-S118 levels, perhaps due to S118 phosphorylation by cdk7, although levels of cdk7 were not different in pre- and post-tamoxifen treatment biopsies (data not shown). However, cdk7-mediated phosphorylation of S118 is dependent on its recruitment to ERz by the association of the TFIIH complex, the recruitment of TFIIH being mediated by the XPD and p62 subunits of TFIIH (Chen et al. 2000), the levels of which were not determined. Furthermore, a recent report indicates that S118 may additionally be phosphorylated by glycogen synthase kinase-3 (GSK-3) (Medunjanin et al. 2005). Altered regulation of TFIIH subunits, including the activity of cdk7 and/or GSK-3 activity could contribute to the elevated S118 phosphorylation observed here. Additionally, an interaction between ERz and the catalytic subunit of protein phosphatase 2A or with protein phosphatase 5 results in dephosphorylation at S118 (Lu et al. 2003, Ikeda et al. 2004). Finally, results from studies in MCF7 cells indicate that ERz turnover, localization and activity are influenced by the activities of different protein kinases, in particular MAPK (Marsaud et al. 2003). Deregulation of any of these activities may contribute to the increased levels of P-S118 in tamoxifen-resistant cases.

We conclude that measurement of P-S118 levels is not indicative of likelihood of failure on endocrine therapies, although changes in P-S118 levels during the course of tamoxifen treatment described here raise the possibility that phosphorylation of ERz at S118 is important in the emergence of resistance. Further, S118 phosphorylation in primary breast tumours is likely to be mediated by MAPK, although MAPK may not be important for S118 phosphorylation following emergence of tamoxifen resistance. Indeed, in a randomized trial using the epidermal growth factor receptor (EGFR) inhibitor Gefitinib (ZD1839, Iressa) given one month prior to surgery, P-S118 levels were reduced in 42 (79%) of 53 tumours, with complete loss of P-S118 staining in 34% of these tumours. There was no significant loss in total ERz following treatment with Gefitinib (Polychronis et al. 2005). Thus, at least for EGFR-positive, ERz-positive cases, S118 phosphorylation is likely to be mediated largely by EGFR-mediated activation of MAPK.

Acknowledgements

We are grateful to members of the laboratory for helpful discussions. Particular thanks go to Dr Laki Buluwela and Dr Ross Thomas for their help with the manuscript. This work was made possible by grants from Cancer Research UK, the Breast Cancer Research Trust and the Tenovus Charity. JMG is in receipt of research grants from AstraZeneca. The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.

References


www.endocrinology-journals.org


Joel PB, Traish AM & Lannigan DA 1995 Estradiol and phorbol ester cause phosphorylation of serine 118 in the human estrogen receptor. Molecular Endocrinology 9 1041–1052.


